Drug Trial Radar · NCT05470413
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
330
Actual
Start
Apr 18, 2022
Primary completion
Oct 31, 2023
Study completion Feb 15, 2024
Sponsor
- Lead sponsor
- Reistone Biopharma Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.
Conditions
- Alopecia Areata
Interventions
SHR0302Drug
SHR0302 4 mg
SHR0302Drug
SHR0302 8 mg
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects achieving a SALT score ≤ 20 at week 24Time frame: 24 weeks
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Chongqing Traditional Chinese Medicine Hospital
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guanzhou, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Wuhan No.1 Hospital
Wuhan, Hubei, China
The second xiangya hospital of central south university
Changsha, Hunan, China
Xiangya Hospital Of Central South University
Changsha, Hunan, China
Dermatology Hospital of Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China
Jiangsu Province People's Hospital
Nanjing, Jiangsu, China
Wuxi No.2 People's Hospital
Wuxi, Jiangsu, China
Jiangxi Provincial Hospital of Dermatology
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
Shengjing Hospital Of China Medical University
Shengyang, Liaoning, China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China
First Hospital Of Shanxi Medical University
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital Of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.